Illumina
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Former unicorn genetics startup Human Longevity loses its horn
The company’s valuation has declined 80 percent, from a $1.6 billion peak to $310 million, according to The Wall Street Journal.
-
Helix and Illumina Accelerator collaborate to aid genomics startups
Helix and Illumina Accelerator have paired up and will give entrepreneurs the chance to develop innovative, DNA-driven products geared toward consumers.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Grail’s high profile CEO steps down after 18-month tenure
Illumina spin-out Grail revealed Wednesday that Jeff Huber is stepping down as CEO of the billion-dollar early cancer detection startup.
-
Grail initiates massive multicenter breast cancer study
The results of the study will serve as a baseline measure for detecting breast cancer in the blood and inform the development of Grail’s pan-cancer screening test.
-
Behind Grail, Illumina’s billion-dollar diagnostics startup
With a billion dollars in private financing and a test projected to generate a terabyte of data per person, Grail has seeded a new category of diagnostics and Big Data. Despite this, the company story shared by CEO Jeff Huber is mostly about people.
-
Philips gets FDA clearance for inpatient continuous monitoring system
This was but one of several pieces of news the Amsterdam-based technology company discussed Monday at HIMSS17.
-
5 snippets from Illumina’s latest earnings call
The leader of the sequencing world is ticking over nicely with sales and revenue, according to Tuesday’s earnings call. But what’s happening behind the scenes? Here we take a look at five trends shaping the future of the company.
-
Bio-Rad acquires RainDance, partners with Illumina for single-cell analysis
Bio-Rad Laboratories has had a busy few weeks, launching a single-cell sequencing system with Illumina and acquiring a major competitor in the digital PCR space, RainDance Technologies. The activity positions the research tools provider for several trends on the horizon, including liquid biopsy.